PRCT PROCEPT BIOROBOTICS CORP

PROCEPT BioRobotics to Report Third Quarter 2023 Financial Results on November 1, 2023

PROCEPT BioRobotics to Report Third Quarter 2023 Financial Results on November 1, 2023

SAN JOSE, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2023 after market close on Wednesday, November 1, 2023. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by following one of the below links:

  • Webcast link for interested listeners:
  • Dial-in registration for sell-side research analysts:

Live audio of the webcast will be available on the “Investors” section of the Company’s website at: .

An archived recording will be available on the “Investors” section of the Company’s website at: . Each webcast will be available for replay for at least 90 days after the event.

About PROCEPT BioRobotics Corporation

PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. The Company has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Investor Contact:

Matt Bacso

VP, Investor Relations and Business Operations



EN
16/10/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PROCEPT BIOROBOTICS CORP

 PRESS RELEASE

PROCEPT BioRobotics® to Attend Four Upcoming Investor Conferences in M...

PROCEPT BioRobotics® to Attend Four Upcoming Investor Conferences in May & June SAN JOSE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that members of management will present at four upcoming investor conferences in May and June. 2025 Bank of America Health Care Conference Location – Las Vegas, NVFireside Chat – Wednesday, May 14 at 3pm PT / 6pm ET 45th Annual William Blair Growth Stock Conference Location –...

 PRESS RELEASE

PROCEPT BioRobotics' Aquablation Therapy Spotlighted at 2025 AUA Annua...

PROCEPT BioRobotics' Aquablation Therapy Spotlighted at 2025 AUA Annual Meeting Along with Expert-Led Workshops Presentations underscore long-term clinical outcomes, safety and durability in BPH treatment Attendees invited to experience hands-on HYDROS Robotic System demonstrations SAN JOSE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- ® Corporation (Nasdaq: PRCT)  (“PROCEPT”), a surgical robotics company whose mission is to revolutionize BPH treatment globally, today announced an extensive lineup of scientific presentations and interactive workshops at the 2025 American Urological Assoc...

 PRESS RELEASE

PROCEPT BioRobotics Reports First Quarter 2025 Financial Results and I...

PROCEPT BioRobotics Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance SAN JOSE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2025. Recent Highlights Total revenue of $69.2 million for the first quarter of 2025, an increase of 55% comp...

 PRESS RELEASE

PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeti...

PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting at the Aria Resort in Las Vegas SAN JOSE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company, whose mission is to revolutionize BPH treatment globally, announced today it will host an in-person investor event on Friday, April 25, 2025, at the Aria Resort in Las Vegas at the American Urological Association Annual Meeting from 8:00am to 9:30am Pacific Time. Guests are encouraged to register in advance by clicking . Registration is recom...

 PRESS RELEASE

WATER III Randomized-Controlled Trial Results Announced at European As...

WATER III Randomized-Controlled Trial Results Announced at European Association of Urology Comparing Aquablation® Therapy to Laser Enucleation Aquablation therapy delivers similar symptom score reduction, superior ejaculatory function preservation, and superior continence preservation to laser enucleation in 80–180 mL prostates in a randomized, multicenter trial SAN JOSE, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company dedicated to advancing patient care through transformative urology solutions, toda...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch